For some breeds, we also offer breed-specific genetic test combinations to test for several hereditary diseases.

Diagnostic spectrum

  • Acatalasemia
  • Achromatopsia (day blindness) (ACHM)
  • Acral mutilation syndrome (AMS)
  • Acute respiratory distress syndrome (ARDS)
  • Afibrinogenemia (AFG)
  • Alaskan Husky encephalopathy (AHE)
  • Alaskan Malamute polyneuropathy (AMPN)
  • Alexander disease (AxD)
  • Amelogenesis imperfecta / Familial enamel hypoplasia (AI/FEH)
  • Behaviour propensity
  • Brachyuria (stumpy tail)
  • Bunny hopping syndrome (BHS1)
  • C3 deficiency (C3)
  • Canine leucocyte adhesion deficiency (CLAD)
  • Canine multi-focal retinopathy (CMR1/2/3)
  • Canine multiple system degeneration (CMSD)
  • Cardiomyopathy with juvenile mortality (CJM)
  • Centronuclear myopathy (CNM)
  • Cerebellar ataxia (CA1)
  • Cerebellar ataxia* (CA)
  • Cerebellar degeneration and myositis complex (CDMC)
  • Cerebellar hypoplasia (CH)
  • Cerebral dysfunction (CDFS)
  • Charcot-Marie-Tooth neuropathy (CMT)
  • Chondrodysplasia (dwarfism)
  • Chondrodysplasia (CDPA) and -dystrophia (CDDY) (IVDD risk)
  • Cleft lip/palate and syndactyly (CLPS)
  • CNS atrophy with cerebellar ataxia (CACA)
  • Collie eye anomaly* (CEA)
  • Color dilution and neurological signs (CDN)
  • Cone degeneration (CD)
  • Congenital hypothyroidism with goiter (CHG)
  • Congenital ichthyosis
  • Congenital idiopathic megaesophagus (CIM)
  • Congenital myasthenic syndrome (CMS)
  • Congenital stationary night blindness (CSNB)
  • Copper storage disease - Copper toxicosis* (CT)
  • Copper storage toxicosis (CT)
  • Craniomandibular osteopathy (CMO)
  • Cystinuria
  • Dandy-Walker-like malformation (DWLM)
  • Degenerative myelopathy exon 1(DM exon1)
  • Degenerative myelopathy exon 2 (DM exon2)
  • Degenerative myelopathy risk modifier (DMRM)
  • Delayed postoperative hemorrhage (DEPOH)
  • Dental-skeletal-retinal anomaly (DSRA)
  • Dermatomyositis (DMS)
  • Digital hyperkeratosis (DH/HFH)
  • Dilated cardiomyopathy (DCM)
  • Dilated cardiomyopathy (DCM)
  • Dilatative cardiomyopathy DCM1 (PDK4)
  • Dilatative cardiomyopathy DCM2 (Titin)
  • Dilated cardiomyopathy (DCM1-4)
  • Disproportionate dwarfism
  • Dry eye curly coat syndrome (CCS)
  • Dyserythropoietic anaemia and myopathy (DAMS)
  • Dystrophic epidermolysis bullosa (DEB)
  • Ectodermal dysplasia/Skin fragility syndrome (ED/SFS)
  • Epidermolytic hyperkeratosis (EHK)
  • Episodic falling (EF)
  • Exercise induced collapse (EIC)
  • Exfoliative cutaneous lupus erythematosus (ECLE)
  • Factor VII deficiency
  • Factor XI deficiency (F11)
  • Familial nephropathy (FN)
  • Familial Nephropathy* (FN)
  • Familial thyroid follicular cell carcinoma (FTFC) - risk analysis
  • Fanconi syndrome
  • Finnish Hound ataxia (FHA)
  • Fucosidosis
  • Gallbladder mucoceles (GBM)
  • Glanzmann thrombasthenia (GT)
  • Glaucoma and goniodysgenesis (GG)
  • Globoid cell leucodystrophy (Krabbe disease)
  • Glycogen storage disease GSD Ia
  • Glycogen storage disease GSD II (Pompe disease)
  • Glycogen storage disease GSD IIIa
  • GM1-Gangliosidosis (GM1)
  • GM2-Gangliosidosis (GM2)
  • Grey Collie syndrome (GCS) (Canine cyclic neutropenia)
  • Haemophilia A (factor VIII deficiency)
  • Haemophilia A (factor VIII deficiency)
  • Haemophilia B (factor IX deficiency)
  • Hemorrhagic diathesis (Scott syndrome)
  • Hereditary ataxia (HA)
  • Hereditary cataract (HSF4)
  • Hereditary cataract (HSF4)*
  • Hereditary deafness (DINGS1&2)
  • Hereditary deafness (EOAD)
  • Hereditary nasal parakeratosis (HNPK)
  • Hereditary nasal parakeratosis (HNPK)
  • Hereditary neuropathy (GHN)
  • Hyperuricosuria (HUU/SLC)
  • Hypomyelination/Shaking puppy syndrome (SPS)
  • Hypophosphatasia (HPP)
  • Ichthyosis
  • Ichthyosis type 2
  • Ichthyosis*
  • Imerslund-Gräsbeck syndrome (IGS)
  • Inflammatory myopathy (IM)
  • Inflammatory pulmonary disease (IPD)
  • Junctional epidermolysis bullosa (JEB)
  • Juvenile brain disease (JBD)
  • Juvenile epilepsy (JE)
  • Juvenile laryngeal paralysis & polyneuropathy (JLPP)
  • Juvenile myoclonic epilepsy (JME)
  • L-2-hydroxyglutaric aciduria (L-2-HGA)
  • Lafora disease (EDTA blood only)
  • Lagotto storage disease (LSD)
  • Laryngeal paralysis with polyneuropathy type 3 (LPPN3)
  • Laryngeal paralysis (LP)
  • Late onset ataxia (LOA)
  • Leonberger polyneuropathy 1 (LPN1)
  • Leonberger polyneuropathy 2 (LPN2)
  • Lethal acrodermatitis (LAD)
  • Lethal lung disease (LAMP3)
  • Leukocyte adhesion deficiency type III (LAD3)
  • Leukoencephalomyelopathy (LEMP)
  • Leukoencephalopathy (LEP)
  • Limb-girdle muscular dystrophy (LGMD)
  • Lundehund syndrome (LHS)
  • Lysosomal storage disease (LSD)
  • Macrothrombocytopenia (MTC)
  • Macular corneal dystrophy (MCD)
  • Malignant hyperthermia (MH)
  • Maxillary canine tooth mesioversion (MCM)
  • May-Hegglin anomaly (MHA)
  • MCAD deficiency
  • MDR1 gene variant (Ivermectin hypersensitivity)
  • Methemoglobinemia (MetHg)
  • Microphthalmia (RBP4)
  • Mitochondrial fission encephalopathy (MFE)
  • Mucopolysaccharidosis type IIIa (MPS3a)
  • Mucopolysaccharidosis type IIIb (MPS3b)
  • Mucopolysaccharidosis type VI (MPS6)
  • Mucopolysaccharidosis type VII (MPS7)
  • Multiocular defect (MOD)
  • Muscular dystrophy (MD)
  • Musladin-Lueke syndrome (MLS)
  • Mycobacterium avium complex sensitivity (MAC)
  • Myostatin mutation ("bully" gene)
  • Myotonia congenita
  • Myxomatous mitral valve disease (MMVD)
  • Narcolepsy
  • Necrotizing meningoencephalitis (NME/PDE)
  • Necrotizing myelopathy (ENM)
  • Nemalin myopathy (NM)
  • Neonatal cortical cerebellar abiotrophy (NCCD)
  • Neonatal encephalopathy with seizures (NEWS)
  • Neuroaxonal dystrophy (NAD)
  • Neuronal ceroid lipofuscinosis (NCL)
  • Neuronal ceroid lipofuscinosis (NCL)
  • Neuronal ceroid lipofuscinosis* (NCL)
  • Obesity
  • Osteochondrodysplasia (OCD)
  • Osteogenesis imperfecta (brittle bone disease)
  • Paradoxical pseudomyotonia (PP)
  • Paroxysmal dyskinesia (PxD)
  • Paroxysmal exercise-induced dyskinesia (PED)
  • Persistent Müllerian duct syndrome (PMDS)
  • Phosphofructokinase deficiency (PFKD)
  • Pituitary dwarfism
  • Polycystic kidney disease (PKD)
  • Postoperative hemorrhage (P2Y12)
  • Prekallikrein deficiency (KLK)
  • Primary ciliary dyskinesia (PCD)
  • Primary hyperoxaluria (PH)
  • Primary immunodeficiency type 2 (PIPS2)
  • Primary lens luxation (PLL)
  • Primary open angle glaucoma (POAG)
  • Primary open angle glaucoma and lens luxation (POAG/PLL)
  • Progressive retinal atrophy (BBS4-PRA)
  • Progressive retinal atrophy (Bas-PRA1)
  • Progressive retinal atrophy (BBS2-PRA)
  • Progressive retinal atrophy (CNGA1-PRA)
  • Progressive retinal atrophy (cord1/crd4-PRA)
  • Progressive retinal atrophy (crd-PRA)
  • Progressive retinal atrophy (crd1-PRA)
  • Progressive retinal atrophy (crd2-PRA)
  • Progressive retinal atrophy (crd3-PRA)
  • Progressive retinal atrophy (dominant PRA)
  • Progressive retinal atrophy (early-onset, eo-PRA)
  • Progressive retinal atrophy (g-PRA)
  • Progressive retinal atrophy (GR-PRA1)
  • Progressive retinal atrophy (GR-PRA2)
  • Progressive retinal atrophy (GUCY2D-PRA)
  • Progressive retinal atrophy (IFT122-PRA)
  • Progressive retinal atrophy (JPH2-PRA)
  • Progressive retinal atrophy (MERTK-PRA)
  • Progressive retinal atrophy (NECAP1-PRA)
  • Progressive retinal atrophy (pap-PRA1)
  • Progressive retinal atrophy (PRA3)
  • Progressive retinal atrophy (PRA4)
  • Progressive retinal atrophy (prcd-PRA)*
  • Progressive retinal atrophy (rcd1-PRA)
  • Progressive retinal atrophy (rcd1a-PRA)
  • Progressive retinal atrophy (rcd2-PRA)
  • Progressive retinal atrophy (rcd3-PRA)
  • Progressive retinal atrophy (rcd4-PRA)
  • Progressive retinal atrophy (Type B1-PRA, HIVEP3)
  • Progressive retinal atrophy (XL-PRA)
  • Progressive retinal atrophy with neurodegeneration (PCYT2 deficiency)
  • Protein losing nephropathy (PLN)
  • Pyruvate dehydrogenase phosphatase 1 deficiency (PDP1)
  • Pyruvate kinase deficiency (PK)
  • Raine syndrome
  • Renal cystadenocarcinoma and nodular fibrosis (RCND)
  • Renal dysplasia and hepatic fibrosis (RDHN)
  • Retinal dysplasia (OSD)
  • Retinal dysplasia* (OSD)
  • Robinow-like syndrome (DVL2)
  • Sensory neuropathy (SN)
  • Severe combined immuno deficiency (SCID)
  • Shar Pei autoinflammatory disease (SPAID)
  • Skeletal dysplasia 2 (dwarfism) (SD2)
  • Spinal dysraphism (NTD)
  • Spinocerebellar ataxia (SCA)
  • Spondylocostal dysostosis (Comma defect)
  • Spongiforme leukoencephalomyelopathy* (SLEM)
  • Spongy degeneration with cerebellar ataxia type 1 (SDCA1)
  • Spongy degeneration with cerebellar ataxia type 2 (SDCA2)
  • Squamous cell carcinoma of the toe - risk analysis
  • Stargardt disease (STGD, retinal degeneration)
  • Startle disease
  • Subacute necrotising encephalopathy (SNE)
  • Succinic semialdehyde dehydrogenase deficiency (SSADHD)
  • Thrombopathia
  • Trapped neutrophil syndrome (TNS)
  • Upper airway syndrome (UAS)
  • van den Ende-Gupta syndrome (VDEGS)
  • Ventricular arrhythmia (IVA)
  • Vitamin D dependent rickets (VDR)
  • von Willebrand disease type 1 (vWD1)
  • von Willebrand disease type 2 (vWD2)
  • von Willebrand disease type 3 (vWD3)
  • Warburg micro syndrome 1 (WARBM1)
  • X-chromosomal severe immunodeficiency (X-SCID)
  • X-linked myopathy (XL-MTM)
  • X-linked retinal dysplasia (XLRD)
  • Xanthinuria type II

    •  

    * partner laboratory